Fresenius v. Baxter: BIO files Amicus Brief in Federal Circuit

Patently BIOtech

The Biotechnology Industry Organization filed an amicus brief at the Federal Circuit in the case of Fresenius v. Baxter:

BIO is concerned that the panel decision could have a number of unintended consequences, such as incentivizing defendants (or declaratory judgment plaintiffs) to employ dilatory tactics in the federal courts while re-arguing already-decided issues under claim construction more favorable to the patent challenger and lower burden-of-proof standards in the PTO.  Courts and parties may be forced to expend considerable time and resources litigating matters that may ultimately become moot.  Such uncertainty would not be conducive to innovation or investment.

Baxter-BIO brief supporting en banc rehearing

Patently BIOtech  |  Email This Post  |  Printer Friendly
Tags: , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>